What are the latest funding news in the synthetic biology market? (September 2026)
Download our beautiful pitch about the synthetic biology market
In our synthetic biology market deck, you will find everything you need to understand the market
This roundup covers 12 publicly announced synthetic biology funding deals disclosed between March 31, 2026 and August 26, 2026.
The deals span automated biofoundries, gene editing, epigenetic medicines, protein-data platforms, molecular discovery, and precision fermentation.
And if you want to better understand this new industry, you can download our pitch covering the synthetic biology market.
Insights
- The 12 disclosed synthetic biology market rounds totaled about $962.7M, but the two largest financings, NewLimit and Serapha Bio, represented roughly 69% of that capital.
- Gene editing, epigenetic regulation, and cell reprogramming accounted for five of the 12 deals but captured about 86% of disclosed funding, showing how therapeutic synthetic biology still attracts the largest checks.
- NewLimit’s $435M Series C was larger than the combined funding disclosed by the seven smallest rounds, underlining the widening gap between late-stage platform companies and early commercialization startups.
- Precision fermentation appeared in four deals, including Standing Ovation, AuX Labs, Melazyme, and StrainX Bioworks, with applications extending beyond food into functional ingredients and industrial biomolecules.
- Three infrastructure-oriented synthetic biology companies, Adaptyv Biosystems, Pumpkinseed, and Generare, raised about $81.6M to improve the data, automation, and experimental workflows behind biological design.
- Europe featured strongly in automated biology and precision fermentation, while the largest therapeutic rounds in this selection were concentrated in the United States and China.
- Several companies are moving from platform validation toward scale-up, which means synthetic biology funding is increasingly supporting manufacturing capacity, clinical preparation, and commercial customer deployment.
As this chart shows, and as featured in our synthetic biology market deck, search interest in gene editing has grown significantly
Summary table of the latest funding deals in the synthetic biology market as of September 2026
We define the synthetic biology market as the set of tools, platforms, and products that rely on engineering biological systems using designed DNA, genetic circuits, or engineered organisms.
We include specialized synbio tools and software, biofoundry and automation platforms, and end-use applications in areas like food, agriculture, health, chemicals, and materials where synthetic biology is a core part of how the product is created or performs.
We exclude conventional biotech and pharmaceuticals, basic GMOs, and traditional fermentation or bio-based products where modern synthetic biology methods are not central to the design or production process.
You can also read our detailed analysis to understand how funding activity in the synthetic biology market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the synthetic biology market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Adaptyv Biosystems | August 26, 2026 | $40M | Series A | Automated biology & protein engineering |
| Epicrispr Biotechnologies | August 11, 2026 | $90M | Series C | Epigenetic medicine & gene regulation |
| Immitra Bio | July 21, 2026 | ~$2.9M | Pre-seed | In-vivo gene editing |
| Serapha Bio | June 23, 2026 | $230M committed | Series A & private placement | In-vivo base editing & genetic medicine |
| NewLimit | June 2, 2026 | $435M | Series C | Cell reprogramming & longevity medicine |
| YolTech Therapeutics | May 29, 2026 | ~$70M | Series C | Gene editing & lipid nanoparticle delivery |
| StrainX Bioworks | May 24, 2026 | ~$13M | Undisclosed | Engineered microbes & precision fermentation |
| Melazyme | May 15, 2026 | $2M | Seed | Precision fermentation & functional biomolecules |
| Pumpkinseed | May 5, 2026 | $20M | Series A | Protein sequencing & biological data |
| AuX Labs | April 21, 2026 | $4M | Funding round | Precision-fermented dairy proteins |
| Generare | April 2, 2026 | ~$21.6M | Series A | Molecular discovery & microbial genomics |
| Standing Ovation | March 31, 2026 | $34.2M | Series B & non-dilutive funding | Precision-fermented dairy proteins |
All the latest funding deals during in the synthetic biology market as of September 2026
Adaptyv Biosystems raised $40M in an August 2026 Series A round.
When was it?
Adaptyv Biosystems announced the financing on August 26, 2026.
Who are they?
Adaptyv Biosystems operates an automated wet lab that generates experimental data for AI-designed proteins.
Geographical focus?
Adaptyv Biosystems is based in Switzerland and is expanding across Europe, including through a planned London laboratory.
Why do we include them in the synthetic biology market?
Adaptyv Biosystems belongs in automated biology and protein engineering because its platform combines cell-free synthetic biology, lab automation, and machine learning.
What is the company stage?
Adaptyv Biosystems is a growth-stage platform company moving from early adopters toward wider pharmaceutical and industrial-biotech use.
How much did they raise?
Adaptyv Biosystems raised approximately $40M in this financing.
What round is it?
Adaptyv Biosystems raised a Series A round led by Highland Europe.
Why did they raise?
Adaptyv Biosystems raised the capital to expand laboratory capacity, grow its Lausanne team, open a London site, and serve more protein-design customers.
Epicrispr Biotechnologies raised $90M in a Series C during August 2026.
When was it?
Epicrispr Biotechnologies announced the oversubscribed financing on August 11, 2026.
Who are they?
Epicrispr Biotechnologies develops programmable epigenetic medicines that switch disease-related genes on or off without permanently changing DNA sequences.
Geographical focus?
Epicrispr Biotechnologies is focused on the United States, initially advancing treatments for neuromuscular diseases such as facioscapulohumeral muscular dystrophy.
Why do we include them in the synthetic biology market?
Epicrispr Biotechnologies belongs in epigenetic medicine and gene regulation because its platform uses engineered systems to control gene expression.
What is the company stage?
Epicrispr Biotechnologies is a clinical-stage company preparing its lead program, EPI-321, for pivotal development.
How much did they raise?
Epicrispr Biotechnologies raised $90M in this round.
What round is it?
Epicrispr Biotechnologies raised a Series C co-led by Octagon Capital and Janus Henderson Investors.
Why did they raise?
Epicrispr Biotechnologies raised the capital to fund pivotal development, expand its pipeline, and increase manufacturing capabilities.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Immitra Bio raised about $2.9M in a pre-seed round during July 2026.
When was it?
Immitra Bio announced the financing on July 21, 2026.
Who are they?
Immitra Bio is developing an in-vivo gene-editing platform designed to correct inherited diseases directly inside patients.
Geographical focus?
Immitra Bio is based in Switzerland and is building treatments for European and global rare-disease markets.
Why do we include them in the synthetic biology market?
Immitra Bio belongs in in-vivo gene editing because its technology uses engineered genetic payloads to modify cells inside the body.
What is the company stage?
Immitra Bio is a preclinical platform company working toward proof of concept for its lead asset.
How much did they raise?
Immitra Bio raised CHF 2.4M, or approximately $2.9M, including a small non-dilutive component.
What round is it?
Immitra Bio raised a pre-seed round co-led by Backbone Ventures and OCCIDENT.
Why did they raise?
Immitra Bio raised the capital to advance its in-vivo editing platform and lead program into preclinical development.
Serapha Bio secured about $230M in committed financing during June 2026.
When was it?
Serapha Bio announced its financing and merger transaction on June 23, 2026.
Who are they?
Serapha Bio is developing a one-time in-vivo base-editing therapy for alpha-1 antitrypsin deficiency.
Geographical focus?
Serapha Bio is focused on U.S. and European development, while its licensing relationship also covers Greater China.
Why do we include them in the synthetic biology market?
Serapha Bio belongs in in-vivo base editing because its lead treatment uses engineered editing machinery to correct a disease-causing mutation in patients.
What is the company stage?
Serapha Bio is a clinical-stage company with proof-of-concept data and a planned U.S. clinical development program.
How much did they raise?
Serapha Bio secured approximately $230M in committed financing, including capital linked to its merger transaction.
What round is it?
Serapha Bio raised a Series A alongside a concurrent private placement associated with a reverse merger.
Why did they raise?
Serapha Bio raised the capital to advance SERP-01 through clinical development and prepare for later-stage studies.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
NewLimit raised $435M in a Series C during June 2026.
When was it?
NewLimit announced the financing on June 2, 2026.
Who are they?
NewLimit develops medicines that use epigenetic reprogramming to restore more youthful behavior in aging human cells.
Geographical focus?
NewLimit is based in the United States and is developing medicines for age-related diseases with global relevance.
Why do we include them in the synthetic biology market?
NewLimit belongs in cell reprogramming and longevity medicine because its platform engineers combinations of transcription factors and biological regulators.
What is the company stage?
NewLimit is a late-preclinical company preparing to enter human clinical testing in 2027.
How much did they raise?
NewLimit raised $435M in this round.
What round is it?
NewLimit raised a Series C led by Founders Fund.
Why did they raise?
NewLimit raised the capital to move its first aging-reprogramming medicine toward human clinical trials.
YolTech Therapeutics raised about $70M in a Series C during May 2026.
When was it?
YolTech Therapeutics announced the financing on May 29, 2026.
Who are they?
YolTech Therapeutics develops in-vivo gene-editing medicines delivered through non-viral lipid nanoparticles.
Geographical focus?
YolTech Therapeutics is based in China and is pursuing international clinical and commercial development, including in the United States.
Why do we include them in the synthetic biology market?
YolTech Therapeutics belongs in gene editing because its HEPDONE platform uses engineered editing systems for durable changes inside patients’ cells.
What is the company stage?
YolTech Therapeutics is a late clinical-stage company with several in-vivo gene-editing programs in development.
How much did they raise?
YolTech Therapeutics raised approximately $70M in this financing.
What round is it?
YolTech Therapeutics raised a Series C led by Loyal Valley Capital.
Why did they raise?
YolTech Therapeutics raised the capital to advance clinical programs and support global clinical development and commercialization preparation.
In our synthetic biology market deck, we identify pain points entrepreneurs should prioritize
StrainX Bioworks raised about $13M in an undisclosed round during May 2026.
When was it?
StrainX Bioworks’ funding round was reported on May 24, 2026.
Who are they?
StrainX Bioworks designs engineered microbial strains that produce nutrition, flavor, and specialty ingredients through precision fermentation.
Geographical focus?
StrainX Bioworks operates across Asia-Pacific, with links to India and commercial ambitions in global ingredient markets.
Why do we include them in the synthetic biology market?
StrainX Bioworks belongs in engineered microbes and precision fermentation because its core work is redesigning microorganisms to produce valuable molecules.
What is the company stage?
StrainX Bioworks is in commercialization and scale-up, moving from research and development toward larger production and customer deployment.
How much did they raise?
StrainX Bioworks raised approximately $13M in the reported financing.
What round is it?
StrainX Bioworks described the financing as an undisclosed round, although some market databases classify it as a Series A.
Why did they raise?
StrainX Bioworks raised the capital to expand strain engineering, improve production economics, and bring precision-fermented ingredients closer to market.
Melazyme raised $2M in a seed round during May 2026.
When was it?
Melazyme announced the seed financing on May 15, 2026.
Who are they?
Melazyme uses engineered microbial fermentation to make melanin and other functional biomolecules for industrial and consumer applications.
Geographical focus?
Melazyme has activity in the United States and Thailand and is targeting international markets for functional ingredients.
Why do we include them in the synthetic biology market?
Melazyme belongs in precision fermentation because its platform uses engineered microbes to produce molecules that are difficult to source through extraction or chemistry.
What is the company stage?
Melazyme is at an early commercialization stage, with production scale-up and initial customer programs underway.
How much did they raise?
Melazyme raised $2M in this seed financing.
What round is it?
Melazyme raised a seed round led by SeaX Ventures.
Why did they raise?
Melazyme raised the capital to scale production, expand partner programs, and support commercial applications for melanin and other biomolecules.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
Pumpkinseed raised $20M in a Series A during May 2026.
When was it?
Pumpkinseed announced the Series A financing on May 5, 2026.
Who are they?
Pumpkinseed has developed a nanophotonic platform that reads protein sequences directly for biological research and drug discovery.
Geographical focus?
Pumpkinseed is headquartered in Palo Alto and serves biopharma customers and government biosecurity programs in the United States.
Why do we include them in the synthetic biology market?
Pumpkinseed belongs in protein sequencing and biological data because its platform creates data needed to design and understand engineered biological systems.
What is the company stage?
Pumpkinseed is an early commercial platform company with active biopharma and government relationships.
How much did they raise?
Pumpkinseed raised $20M in this financing.
What round is it?
Pumpkinseed raised a Series A co-led by NFX and Future Ventures.
Why did they raise?
Pumpkinseed raised the capital to scale its sequencing platform, deepen partnerships, and develop AI models using its proteomic datasets.
AuX Labs raised $4M for its dairy-protein platform during April 2026.
When was it?
AuX Labs announced the financing on April 21, 2026.
Who are they?
AuX Labs uses precision fermentation to produce real dairy proteins for animal-free cheese products.
Geographical focus?
AuX Labs is based in Canada and is using partnerships to target foodservice and consumer markets across North America.
Why do we include them in the synthetic biology market?
AuX Labs belongs in precision-fermented dairy because engineered microorganisms produce its casein and other dairy proteins without cows.
What is the company stage?
AuX Labs is in commercialization, with pilot customers, GRAS self-affirmation for its casein, and broader launch preparations underway.
How much did they raise?
AuX Labs raised $4M in this round.
What round is it?
AuX Labs described the transaction as a funding round, while some market databases classify it as a Series A.
Why did they raise?
AuX Labs raised the capital to scale manufacturing, hire talent, build foodservice partnerships, and commercialize its cheese-protein platform.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Generare raised about $21.6M in a Series A during April 2026.
When was it?
Generare announced the financing on April 2, 2026.
Who are they?
Generare discovers new molecules by mining microbial genomes, expressing gene-derived compounds, and generating experimental datasets.
Geographical focus?
Generare is based in France and is building a platform for partnerships with pharmaceutical and biotechnology companies worldwide.
Why do we include them in the synthetic biology market?
Generare belongs in molecular discovery because its workflow uses synthetic biology to identify, express, and characterize compounds encoded in microbial DNA.
What is the company stage?
Generare is a growth-stage platform company expanding its molecular library, research capabilities, and industrial partnerships.
How much did they raise?
Generare raised €20M, or approximately $21.6M, in this financing.
What round is it?
Generare raised a Series A co-led by Alven and Daphni.
Why did they raise?
Generare raised the capital to expand its dataset, research capacity, and ability to produce new molecules for drug-discovery programs.
Standing Ovation raised $34.2M to scale dairy proteins during March 2026.
When was it?
Standing Ovation announced the financing on March 31, 2026.
Who are they?
Standing Ovation uses precision fermentation to produce animal-free casein and other proteins for cheese, nutrition, and pet food.
Geographical focus?
Standing Ovation is based in France and is initially prioritizing commercialization in North America before expanding into Europe and Asia.
Why do we include them in the synthetic biology market?
Standing Ovation belongs in precision-fermented dairy because engineered microorganisms make its casein and other dairy proteins without animals.
What is the company stage?
Standing Ovation is at commercial scale-up stage, increasing manufacturing capacity and preparing broader market launches.
How much did they raise?
Standing Ovation raised $34.2M in total financing, including approximately $28.5M in equity and $5.7M in non-dilutive funding.
What round is it?
Standing Ovation raised a Series B for the equity component, alongside non-dilutive financing.
Why did they raise?
Standing Ovation raised the capital to expand manufacturing and support the commercial rollout of its dairy proteins, particularly in North America.
Related blog posts
- The evolution of funding activity in synthetic biology
- The main fundraising trends in synthetic biology
- How strong is fundraising in the synthetic biology market right now?
